PDF: Neoadjuvant Immunotherapy in the Management of Cutaneous Squamous Cell Carcinoma

PDF Download: Neoadjuvant cemiplimab has shown promising results for resectable cutaneous squamous cell carcinoma where surgery may result in significant morbidity. Phase 2 studies demonstrated pathological complete response rates of 51% with event-free survival of 89% at 12 months. The treatment was well-tolerated and may improve surgical outcomes by reducing tumor burden before resection, offering a valuable option for advanced disease.
Read online:
Neoadjuvant Immunotherapy in the Management of Cutaneous Squamous Cell Carcinoma